#1 Clinical Trials Search in Europe

Study on Bimekizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis

1 1

What is this study about?

This clinical trial is focused on studying the effects of two treatments for moderate to severe plaque psoriasis in children and teenagers aged 6 to less than 18 years. Plaque psoriasis is a skin condition that causes red, scaly patches on the skin. The study will compare the effectiveness and safety of two medications: bimekizumab and ustekinumab. Bimekizumab, also known by its code name UCB4940, and ustekinumab are both given as a solution for injection under the skin.

The purpose of the study is to evaluate how well bimekizumab works compared to ustekinumab in treating children and adolescents with this condition. Participants will receive either bimekizumab, ustekinumab, or a placebo, which is a substance with no active medication. The study will last for a period of time, during which participants will receive regular injections and attend follow-up visits to monitor their progress and any side effects.

Throughout the study, doctors will assess the improvement in the skin condition using specific measures, such as the Psoriasis Area and Severity Index (PASI) and the Investigator’s Global Assessment (IGA). These assessments will help determine the effectiveness of the treatments. The study will also monitor any changes in the participants’ overall health, including growth and quality of life, to ensure the safety of the treatments being tested.

1 initial treatment period

During this period, the participant will receive either bimekizumab or ustekinumab through subcutaneous injections. The specific dosage and frequency will be determined by the study protocol.

The primary goal is to assess the effectiveness of the treatment by measuring the improvement in skin condition using the Psoriasis Area Severity Index (PASI) and the Investigator’s Global Assessment (IGA) at Week 16.

2 maintenance period

Following the initial treatment period, the participant will continue to receive the assigned treatment to maintain the improvements achieved.

The participant’s response will be monitored at various intervals, including Week 48, to evaluate long-term effectiveness and safety.

3 safety and efficacy assessments

Throughout the trial, regular assessments will be conducted to monitor the participant’s health and the treatment’s impact. This includes checking for any adverse effects and changes in vital signs, physical examination findings, and laboratory results.

The participant’s quality of life and any changes in symptoms will also be evaluated using specific questionnaires and scales.

4 end of study evaluations

At the conclusion of the study, final assessments will be performed to determine the overall effectiveness and safety of the treatment.

The participant’s progress and any long-term effects of the treatment will be documented and analyzed.

Who Can Join the Study?

  • The participant must be between 6 and less than 18 years old at the time of signing the consent form.
  • The participant must have been diagnosed with moderate to severe plaque psoriasis for at least 3 months before the screening visit. Plaque psoriasis is a skin condition that causes red, scaly patches.
  • At both the screening and baseline visits, the participant must have:
    • Body surface area (BSA) affected by psoriasis of 10% or more. This means that at least 10% of the skin is affected by psoriasis.
    • An Investigator’s Global Assessment (IGA) score of 3 or more on a scale from 0 to 4. This score helps to measure the severity of psoriasis.
    • A Psoriasis Area and Severity Index (PASI) score of 12 or more, or a PASI score of 10 or more with at least one of the following:
      • Significant involvement of the face.
      • Significant involvement of the genital area.
      • Significant involvement of the hands and feet.
  • The participant must be eligible for systemic psoriasis therapy, which involves medication that affects the whole body, and/or phototherapy or chemotherapy, as well as treatment with ustekinumab, according to its guidelines.
  • The participant must weigh at least 15 kg and have a body mass index (BMI) for their age in the 5th percentile or higher at the screening. BMI is a measure that uses height and weight to estimate body fat.

Who Cannot Join the Study?

  • Patients who have any other serious health conditions that could interfere with the study.
  • Patients who are currently participating in another clinical trial.
  • Patients who have had a recent infection that required treatment with antibiotics.
  • Patients who have a history of allergic reactions to similar medications.
  • Patients who are pregnant or breastfeeding.
  • Patients who have received certain vaccines recently.
  • Patients who have a history of drug or alcohol abuse.
  • Patients who have certain blood disorders.
  • Patients who have a weakened immune system.
  • Patients who have had a recent surgery.
  • Patients who have certain skin conditions other than psoriasis.
  • Patients who have a history of cancer.
  • Patients who have liver or kidney problems.
  • Patients who have uncontrolled high blood pressure.
  • Patients who have heart problems.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Technische Universitaet Dresden Dresden Germany
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Rome Italy
Dermed Centrum Medyczne Sp. z o.o. Lodz Poland
Center For Pediatric And Adolescent Medicine Of The Johannes Gutenberg University Mainz Mainz Germany
Oncopole Claudius Regaud Toulouse France

Other Sites

Site Name City Country Status
Centre Hospitalier Victor Dupouy Argenteuil France
Azienda Ospedaliero-Universitaria Policlinico G. Rodolico-San Marco Di Catania Catania Italy
Centre hospitalier universitaire de Liege Liege Belgium
Hospital Sant Joan De Deu Barcelona Esplugues De Llobregat Spain
Universitaetsklinikum Schleswig-Holstein AöR Kiel Germany
Wojewodzki Specjalistyczny Szpital Im Dr Wl Bieganskiego Lodz Poland
Twoja Przychodnia Szczecinskie Centrum Medyczne Sp. z o.o. Szczecin Poland
Twoja Przychodnia Nowosolskie Centrum Medyczne Sp. z o.o. Nowa Sol Poland
Hospital Universitario Virgen De Las Nieves Granada Spain
Katholisches Kinderkrankenhaus Wilhelmstift gGmbH Hamburg Germany
Renew Clinic Sp. z o.o. Bialystok Poland
Hospital General Universitario De Alicante Alicante Spain
Fakultni Nemocnice Plzen Plzen Czechia
Uniwersytecki Szpital Kliniczny Im.Fryderyka Chopina W Rzeszowie Rzeszow Poland
University Of Debrecen Debrecen Hungary
Somogy Varmegyei Kaposi Mor Oktato Korhaz Kaposvar Hungary
Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak sp.p. Wroclaw Poland
Universitaetsklinikum Erlangen AöR Erlangen Germany
Charite Universitaetsmedizin Berlin KöR Berlin Germany
Universita’ Di Pisa Pisa Italy
Universita’ Politecnica Delle Marche Ancona Italy
Universidade De Santiago De Compostela Santiago De Compostela Spain
Rheinische Friedrich-Wilhelms-Universitaet Bonn Bonn Germany
Centre Hospitalier Universitaire De Nantes Nantes France
University Of Szeged Szeged Hungary
Camvkavsl Umwpakhcyovtxu Squcprmbs Woluwe-Saint-Lambert Belgium
Tssljhmzzoc uzv Sjgiazpefak Bhbzksak Gebv Bad Bentheim Germany
Uomfxxstkqdtkvidfuqhw Mjnsffdl Atb Munster Germany
Gkpjjy Ukkkzydqcc Feoetcidw Frankfurt Germany
Dbgtstchuq Sgc z oqqr Wroclaw Poland
Hqjozxin Dz Lx Svyvy Cuke I Srcx Psb Barcelona Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Belgium Belgium
Recruiting
31.07.2024
Czechia Czechia
Recruiting
31.07.2024
France France
Not recruiting
31.07.2024
Germany Germany
Recruiting
31.07.2024
Hungary Hungary
Recruiting
31.07.2024
Italy Italy
Recruiting
31.07.2024
Poland Poland
Recruiting
31.07.2024
Spain Spain
Recruiting
31.07.2024

Trial locations

Investigated drugs:

Bimekizumab is a medication being studied for its effectiveness in treating moderate to severe plaque psoriasis in children and adolescents. It is given as an injection under the skin. The goal is to see how well it works in reducing the symptoms of psoriasis, which is a skin condition that causes red, scaly patches.

Ustekinumab is another medication used in this study as a comparison to bimekizumab. It is also used to treat moderate to severe plaque psoriasis and is administered through an injection. The study aims to compare the effectiveness and safety of ustekinumab with bimekizumab in managing psoriasis symptoms in young patients.

Moderate to Severe Plaque Psoriasis – This is a chronic skin condition characterized by red, scaly patches that can appear anywhere on the body. The patches, known as plaques, are often itchy and can be painful. The disease occurs when skin cells multiply faster than normal, leading to a buildup of cells on the skin’s surface. It typically progresses with periods of flare-ups and remission. The severity can vary, with moderate to severe cases covering larger areas of the body and causing more significant discomfort. Environmental factors, stress, and certain medications can trigger or worsen the symptoms.

Trial ID:
2023-503859-10-00
Protocol code:
PS0021
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • ORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis

    Recruiting

    1
    Germany Spain

  • A study to evaluate the effectiveness and safety of zasocitinib in children and adolescents with moderate-to-severe plaque psoriasis

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Poland Spain